{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3598","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalComment":"Strata: by intolerance to imatinib treatment","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"13.3","value":"8.3"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"10.9","value":"7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) GIST specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"OG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"The KIT Exon 11 Intent to Treat (ITT) Population is defined as all patients who are designated as having a mutation in KIT Exon 11 at the time of randomization. Patients in this population will be analyzed according to the treatment they were scheduled to receive.","reportingStatus":"POSTED","timeFrame":"From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)","title":"Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population","type":"PRIMARY","unitOfMeasure":"months"}